Rheumatoid arthritis and risk of non-tuberculous mycobacterial pulmonary disease: a nationwide longitudinal cohort study Authors: Bumhee Yang, Kyungdo Han, Jin-Hyung Jung, Wonyoung Jung, Bo-Guen Kim, Yeonghee Eun, Hyungjin Kim, Dong Wook Shin, Hyun Lee Published: 2025 ABSTRACT AbstractBackgroundPrevious literature suggested that rheumatoid arthritis (RA) might be a risk factor for nontuberculous mycobacteria pulmonary disease (NTM-PD). However, longitudinal studies did not comprehensively consider potential confounders such as body mass index and smoking status. In addition, the impact of RA seropositivity has not been well elucidated. In this study, we aimed to evaluate the risk of incident NTM-PD in subjects with RA versus age-matched and sex-matched controls, while focusing on the impact of RA serologic status on this association.MethodsFrom the Korean National Health Insurance Service data from 2010 to 2017, we identified 60 315 participants aged ≥20 years with RA and 301 575 without RA who were age-matched and sex-matched 1:5. The participants were followed up from 1 year after RA diagnosis (or the corresponding index date for matched controls) to the date of NTM-PD diagnosis, censored date or 31 December 2019, whichever occurred first.ResultsDuring a median 4.5 (IQR, 2.6–6.4) year follow-up, NTM-PD occurred in 0.23% and 0.06% of the RA and matched cohort (incidence: 0.54 and 0.14 per 1000 person-years), respectively. Compared with controls, participants with RA had a 3.11-fold (95% CI 2.50 to 3.88) higher risk of NTM-PD. In the subgroup analysis stratified by seropositivity, seropositive patients with RA had a 3.77-fold (95% CI 3.00 to 4.73) higher risk of NTM-PD than controls, whereas participants with seronegative RA did not have a significantly higher risk (adjusted HR 1.18, 95% CI 0.68 to 2.04). Stratified analyses showed a more prominent association of RA with NTM-PD in males, alcohol drinkers and obese individuals (p<0.05).ConclusionThe risk of incident NTM-PD was approximately threefold higher in participants with RA than in matched controls, although the association was significant only for patients with seropositive RA.Keywords: Clinical Epidemiology, Tuberculosis WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS The results show that the risk of incidents with NTM-PD was higher in participants with RA than in matched controls. The results show that the risk of incidents with NTM-PD was higher in participants with RA than in matched controls. In addition, subgroup analysis of the seropositive RA (SPRA) and seronegative RA groups based on serologic status showed that the risk of NTM-PD was higher only in participants with SPRA. In addition, subgroup analysis of the seropositive RA (SPRA) and seronegative RA groups based on serologic status showed that the risk of NTM-PD was higher only in participants with SPRA. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Our findings emphasise the need for heightened awareness of pneumonia risk in the management of RA. Our findings emphasise the need for heightened awareness of pneumonia risk in the management of RA. Introduction Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease with significant morbidity and mortality that exerts an increasing burden on health resources worldwide.1,3 In the past 20 years, advances in RA treatment, especially the use of disease-modifying antirheumatic drugs (DMARD) such as methotrexate (MTX) and several biologic DMARDs (bDMARDs),4 have substantially improved articular outcomes in patients with RA. However, the immunosuppressive treatment effects increase the risk of various pulmonary infections, such as pneumonia and mycobacterial infection.5,7 Nontuberculous mycobacteria (NTM) are a bacterial species other than Mycobacterium tuberculosis complex and Mycobacterium leprae. NTM are ubiquitous in soil, naturally occur in municipal water systems and can cause opportunistic infections, especially in the lungs.8 9 The prevalence and disease burden of NTM-induced pulmonary disease (NTM-PD) are increasing globally, and NTM-PD is recognised as an important comorbidity that occurs in many chronic diseases, including RA.10 Several studies have demonstrated a positive relationship between RA and NTM-PD.311,18 However, many of these studies were limited by a relatively small sample,14,16 cross-sectional design,11 12 15 16 a lack of control groups (non-RA population)3 11 14 17 or a lack of consideration of some demographics (eg, body mass index (BMI)),13 19 lifestyles (eg, smoking, alcohol consumption or physical activity)13 16 19 or immunosuppressive drugs11 18 that might increase the NTM-PD risk. In addition, only a few studies have considered the serological status of RA.15 Thus, large-scale longitudinal studies with comprehensive data on the abovementioned factors are needed. This study was conducted with an aim to compare the incidence and risk of NTM-PD between a cohort with RA and age-matched and sex-matched non-RA controls drawn from a large, nationally representative longitudinal database in South Korea. Additionally, we evaluated the impact of lifestyles and the RA serologic status on the association of RA with the risk of NTM-PD. Methods Data source and setting In this cohort study, we used data from the National Health Insurance Service (NHIS), which is a universal social insurance programme that covers 97% of the Korean population (approximately 50 million people). The NHIS dataset includes information on demographic variables (age, sex, etc), socioeconomic status (income level, residential area, etc), healthcare utilisation (outpatient department, emergency room visit, hospitalisation, etc), health screening examination findings, disease diagnosis based on the International Classification of Disease (ICD-10) codes (10th revision), medical treatment, procedures and surgery.20 The NHIS database includes various medical and health information and has been widely used in epidemiological studies to identify risk factors for certain diseases.21,23 In South Korea, annual or biennial free health screening examination programmes are offered to all Korean citizens by the Ministry of Health and Welfare. In 2009, the health screening examination included anthropometric measurements, such as BMI; questionnaires pertaining to smoking, alcohol consumption and physical activity; blood tests including lipid levels and chest radiography. The current participation rate in health screening examinations ranges from 70% to 80%. After anonymisation, the Korean government provides representative data from health screening examinations for enabling research.20 The study protocol was approved by the institutional review board of the Samsung Medical Center (IRB No. SMC 2022-06-141). The requirement for informed consent was waived because the NHIS database uses a deidentified patient identification system. Study participants Among patients diagnosed with RA between 2010 and 2017 who were eligible for the study, we identified 119 788 with RA (83 064 with seropositive RA (SPRA) and 36 724 seronegative RA (SNRA)) using the following criteria: (1) individuals who had a registered diagnostic code for RA (ICD-10 M05 for SPRA and M06, except M06.1 and M06.4, for SNRA) and (2) those who had been prescribed any DMARD, including conventional synthetic DMARDs, bDMARDs and target-specific DMARDs (tsDMARDs). We initially included 64 457 participants (45 045 with SPRA and 19 412 with SNRA) who were diagnosed with RA and whose health screening examination data within 2 years preceding the RA diagnosis (between 2010 and 2017) were available. After excluding individuals with other connective tissue diseases (n=213), those with missing data of health screening examination (n=2321), those who were younger than 20 years (n=6), those who were previously diagnosed with NTM (n=136) or diagnosed with NTM within 1 year after RA diagnosis (n=569), to minimise the risk of reverse causality, a total of 61 212 potential participants were identified for the RA cohort. Of these, 60 315 participants (42 062 with SPRA and 18 253 with SNRA) were eligible for 1:5 age and sex matching. To establish age-matched and sex-matched controls, from among 1 207 831 subjects who were approximately 1:10 age-matched and sex-matched to the 1 19 788 patients with RA, we included 677 322 participants who underwent health screening examinations in the same year as the matched participants with RA. After excluding participants with other rheumatic diseases (n=20), those with missing data on health screening examinations (n=30 705), those younger than 20 years (n=706), those diagnosed with previous NTM-PD before matching (n=379) and those diagnosed with NTM-PD within 1 year after matching, there were 643 122 participants in the matched controls. Of these, 301 575 participants were eligible for 1:5 age and sex matching with the RA cohort (figure 1). Flowchart depicting the screening and enrolment of the study population. NTM-PD, nontuberculous mycobacteria-induced pulmonary disease; RA, rheumatoid arthritis; SNRA, seronegative rheumatoid arthritis; SPRA, seropositive rheumatoid arthritis. Exposure The exposure in this study was RA, which included SPRA and SNRA. Separate operational definitions were applied to each group to identify patients with SPRA and SNRA in each group.24 The NHIS operates the Rare and Intractable Disease (RID) programme for patients with certain diseases and provides cost-reductive actions for relevant medical expenses related to these diseases. For participants with RA, SPRA is only eligible for registration in the RID programme when the following criteria are satisfied: a positive result for rheumatoid factor or anticyclic citrullinated peptide antibody and an official physician’s certificate that the patient meets the RA classification criteria. Participants with SPRA were defined based on whether their claim record included the ICD-10 diagnostic code M05, the RID registration code V223 and a record of prescriptions for any DMARDs, including conventional synthetic DMARDs (MTX, hydroxychloroquine, leflunomide, sulfasalazine, tacrolimus, cyclosporine, D-penicillamine, bucillamine, azathioprine, minocycline or mizoribine), bDMARDs (adalimumab, etanercept, infliximab, golimumab, rituximab, abatacept, tocilizumab) or tsDMARDs (tofacitinib) for at least 180 days. For SNRA, participants who visited hospitals with diagnostic codes of ICD-10 M06 (except for M06.1 and M06.4) and had a prescription record of DMARDs for ≥180 days were defined as participants with SNRA.24 The index date was defined as the date on which the RA-related diagnostic code was first registered. Outcomes The outcome of this study was the incidence of NTM-PD, which was defined by the following criteria: (1) newly claimed ICD-10 diagnosis code A31.0; (2) at least two ambulatory visits or hospitalisations with an A31.0, diagnosis code within 1 year after the initial claim.25 The participants were followed up from 1 year after the RA diagnosis (or the corresponding index date for matched controls) to the date of NTM-PD diagnosis, censored date, or 31 December 2019, whichever occurred first. Covariates Household income was categorised into quartiles based on insurance premium levels, which were determined by income level, and participants covered by Medical Aid (poorest 3%) were merged into the lowest income quartile26,28 and designated ‘low income’. Lifestyles, including smoking status, alcohol consumption and physical activity, were assessed using a self-reported questionnaire. Smoking status was divided into never, ex-smokers and current smokers. Ex-smokers and current smokers were assigned to subgroups based on 20 pack-years. Alcohol consumption was classified as none, 1–2 times a week, 3–4 times a week or almost every day. ‘Regular exercise’ was defined as moderate-intensity exercise for >5 days per week or vigorous exercise for >3 days per week.29 BMI was calculated as body weight divided by the square of height (kg/m2) and classified into one of the following four groups: underweight (<18.5 kg/m2), normal (18.5–22.9 kg/m2), overweight (23.0–24.9 kg/m2) and obese (≥25 kg/m2) according to the classification for Asians.30 The definitions of comorbidities (diabetes mellitus, hypertension, dyslipidaemia, chronic kidney disease, ischaemic heart disease and airway diseases (asthma, chronic obstructive pulmonary disease or bronchiectasis)) were based on ICD-10 codes, as previously described.27 28 31 32 Additionally, tuberculosis was defined using the ICD-10 codes and registered with the national RID support programme.27 28 Statistical analysis Descriptive statistics are presented as the frequency (proportion) for categorical variables and mean±SD for continuous variables. We compared the two groups using the χ2 test for categorical variables and the t-test for continuous variables. The incidence rates of NTM-PD were calculated by dividing the number of incident events by the total follow-up period (1000 person-years). A cumulative incidence plot was used to estimate the incidence of NTM-PD between the RA and matched cohorts, and the log-rank test was used to evaluate significant differences between groups. The risk of incident NTM-PD in the RA cohort compared with that in the matched cohort was estimated using univariate and multivariate Cox proportional hazards regression analyses. Model one was adjusted for age, sex, income, smoking, alcohol consumption, physical activity and BMI. Model 2 was further adjusted for diabetes mellitus, hypertension, dyslipidaemia, chronic kidney disease, airway diseases and tuberculosis. Stratified analyses were performed according to sex, age, income, smoking, alcohol consumption, regular exercise, BMI and comorbidities, including airway diseases and tuberculosis. Additionally, all analyses were performed in equally divided groups according to RA serologic status. Statistical significance was defined as a two-sided p value of <0.05. All the statistical analyses were performed using SAS V.9.4 (SAS Institute, Cary, North Carolina, USA). Patient and public involvement Patients and the public were not involved in the design or conduct of this research. Results Baseline characteristics In the study population, the mean age was 56.5 (SD, 12.1) years and 25.7% of the cohort were men. The proportions of pulmonary and extrapulmonary comorbidities were higher in the RA cohort than in the matched cohort (p<0.001 for all), except for diabetes mellitus (p=0.418). Additionally, compared with the matched cohort, there were fewer never-smokers, alcohol drinkers and regular exercisers in the RA cohort (p<0.001) than in the matched cohort. The BMI was lower in the RA cohort than in the matched cohort (p<0.001). The SNRA group had a higher proportion of males, younger participants and fewer never-smokers than the SPRA group (p<0.001 for all). Additionally, participants with SNRA consumed more alcohol, engaged in regular exercise more frequently and had a higher BMI than those with SPRA (p<0.001 for all). All comorbidities, except diabetes mellitus (p=0.505) and tuberculosis (p=0.119), were observed more frequently in participants with SNRA than in those with SPRA. However, airway diseases were more common in participants with SPRA than in those with SNRA (p<0.001; table 1). Table 1Baseline characteristics of the participantsVariablesTotal(n=3 61 890)RA statusSerological RA statusNo(n=3 01 575)Yes(n=60 315)P valueSPRA(n=42 062)SNRA(n=18 253)P valueAge, years56.5±12.156.5±12.156.5±12.1>0.99957.4±11.654.4±12.7<0.001 20–3928 092 (7.8)23 410 (7.8)4682 (7.8)>0.9992379 (5.7)2303 (12.6)<0.001 40–64237 366 (65.6)197 805 (65.6)39 561 (65.6)27 683 (65.8)11 878 (65.1) ≥6583 011 (22.9)69 250 (22.6)13 761 (22.8)12 000 (28.5)4072 (22.3)Male sex93 066 (25.7)77 555 (25.7)15 511 (25.7)>0.99910 171 (24.2)5340 (29.3)<0.001BMI, kg/m2<0.001<0.001 Underweight (<18.5)12 551 (3.4)9874 (3.2)2677 (4.4)1897 (4.5)780 (4.2) Normal (18.5–23.0)143 718 (39.7)118 207 (39.2)25 511 (42.3)18 119 (43.0)7392 (40.5) Overweight (23.0–25.0)88 754 (24.5)74 453 (24.6)14 301 (23.7)9982 (23.7)4319 (23.6) Obese (≥25.0)116 867 (32.2)99 041 (32.8)17 826 (29.5)12 064 (28.6)5762 (31.5)Smoking<0.001<0.001 Never smoker285 419 (78.8)238 555 (79.1)46 864 (77.7)33 003 (78.4)13 861 (75.9) Ex-smoker (<20 PY)21 677 (5.9)17 931 (5.95)3746 (6.2)2274 (5.4)1472 (8.0) Ex-smoker (≥20 PY)13 673 (3.7)10 953 (3.63)2720 (4.5)1884 (4.4)836 (4.5) Current smoker (<20 PY)22 981 (6.3)19 355 (6.42)3626 (6.0)2315 (5.5)1311 (7.1) Current smoker (≥20 PY)18 140 (5.0)14 781 (4.9)3359 (5.5)2586 (6.1)773 (4.2)Alcohol drinking109 691 (30.3)94 262 (31.2)15 429 (25.5)<0.00110 211 (24.2)5218 (28.5)<0.001Regular exercise71 269 (19.6)60 529 (20.0)10 740 (17.8)<0.0017296 (17.3)3444 (18.8)<0.001Low income73 652 (23.5)61 362 (23.5)12 290 (23.5)0.4319864 (23.5)3897 (21.3)<0.001Comorbidities Diabetes mellitus45 222 (12.5)37 625 (12.4)7597 (12.6)0.4185273 (12.5)2324 (12.7)0.505 Hypertension131 900 (36.4)108 131 (35.8)23 769 (39.4)<0.00116 387 (38.9)7382 (40.4)<0.001 Dyslipidaemia112 071 (30.9)92 802 (30.7)19 269 (31.9)<0.00113 135 (31.2)6134 (33.6)<0.001 CKD24 266 (6.7)19 342 (6.4)4924 (8.1)<0.0013327 (7.91)1597 (8.7)<0.001 Airway diseases61 457 (16.9)46 206 (15.3)15 251 (25.2)<0.00110 818 (25.7)4433 (24.2)<0.001 Tuberculosis759 (0.2)411 (0.1)348 (0.5)<0.001256 (0.6)92 (0.5)0.119Data are presented as the mean ± SD or frequency (proportion).CKD, chronic kidney disease.BMI, body mass index; PY, pack-years; RA, rheumatoid arthritis; SNRA, seronegative rheumatoid arthritis; SPRA, seropositive rheumatoid arthritis. Baseline characteristics of the participants Data are presented as the mean ± SD or frequency (proportion). CKD, chronic kidney disease.BMI, body mass index; PY, pack-years; RA, rheumatoid arthritis; SNRA, seronegative rheumatoid arthritis; SPRA, seropositive rheumatoid arthritis. Incidence and risk of NTM-PD During a median follow-up period of 4.5 (IQR, 2.6–6.4) years, 0.23% (147/60 375) of the RA cohort and 0.06% (189/301 575) of the matched cohort developed NTM-PD, with incidence rates of 0.54 and 0.14 per 1000 person-years, respectively (p<0.001). Even after adjusting for potential confounders, the risk of incident NTM-PD was significantly higher in the RA cohort than in the matched cohort (unadjusted HR 3.95, 95% CI 3.18 to 4.90; adjusted HR in model 1 3.67, 95% CI 2.96 to 4.56; adjusted HR in model 2 3.11, 95% CI 2.50 to 3.88; table 2). Similarly, the cumulative incidence plot showed a significantly higher incidence of NTM-PD in the RA cohort than in the matched cohort (log-rank p<0.001; figure 2A). Table 2Risk of NTM-PD according to RA status and serological RA statusGroupingNumber at risk (N)NTM-PD(n)Duration(PY)Incident rate (/1000 PY)Unadjusted modelHR (95% CI)Model 1aHR (95% CI)Model 2aHR (95% CI)By RA status Control301 5751891 371 419.90.14ReferenceReferenceReference RA60 315147270 318.50.543.95 (3.18 to 4.90)3.67 (2.96 to 4.56)3.11 (2.50 to 3.88)By RA status and seropositivity Control301 5751891 371 419.90.14ReferenceReferenceReference SNRA18 2531480 343.70.171.28 (0.74 to 2.19)1.34 (0.78 to 2.3)1.18 (0.68 to 2.04) SPRA42 062133189 974.90.705.07 (4.07 to 6.33)4.51 (3.61 to 5.63)3.77 (3.00 to 4.73)By seropositivity SNRA18 2531480 343.70.17ReferenceReferenceReference SPRA42 062133189 974.90.703.97 (2.3 to 6.89)3.45 (1.98 to 5.98)3.25 (1.87 to 5.66)Model 1 was adjusted for age, sex, body mass index, smoking, alcohol consumption, physical activity and low-income status.Model 2 was further adjusted for diabetes mellitus, hypertension, dyslipidaemia, chronic kidney disease, airway disease and tuberculosis, in addition to the variables in model 2.SPRA, seropositive rheumatoid arthritis.aHR, adjusted HR; NTM-PD, nontuberculous mycobacterial pulmonary lung disease; PY, person-years; RA, rheumatoid arthritis; SNRA, seronegative rheumatoid arthritis. Risk of NTM-PD according to RA status and serological RA status Model 1 was adjusted for age, sex, body mass index, smoking, alcohol consumption, physical activity and low-income status. Model 2 was further adjusted for diabetes mellitus, hypertension, dyslipidaemia, chronic kidney disease, airway disease and tuberculosis, in addition to the variables in model 2. SPRA, seropositive rheumatoid arthritis.aHR, adjusted HR; NTM-PD, nontuberculous mycobacterial pulmonary lung disease; PY, person-years; RA, rheumatoid arthritis; SNRA, seronegative rheumatoid arthritis. Cumulative incidence of NTM-PD according to (A) rheumatoid arthritis status and (B) serological status of rheumatoid arthritis. NTM-PD, nontuberculous mycobacteria-induced pulmonary disease RA, rheumatoid arthritis; SNRA, seronegative rheumatoid arthritis; SPRA, seropositive rheumatoid arthritis. RA serological status and incidence and risk of NTM-PD When RA was classified according to serological status, NTM-PD occurred in 0.08% (n=14/18 253) and 0.32% (n=133/42 062) of the SNRA and SPRA cohorts (incidence rates of 0.70 and 0.17 per 1000 person-years; p<0.001), respectively (table 2). Compared with matched controls, the risk of incident NTM-PD was 3.77-fold (95% CI=3.00–4.73) higher in the SPRA cohort, whereas the risk did not increase significantly in the SNRA cohort (adjusted HR in model 2 1.18, 95% CI 0.68 to 2.04). The risk of NTM-PD was 3.25-fold (95% CI 1.87 to 5.66) higher in the SPRA than in the SNRA cohort (model 2). Similarly, the cumulative incidence plot showed a significantly higher incidence of NTM-PD in the SPRA cohort than in the SNRA cohort (log-rank p<0.001; figure 2B). Stratified analysis Socioeconomic characteristics, smoking status, health behaviour and comorbid conditions did not show a significant interaction between RA and the risk of NTM-PD (p value for interaction >0.05 for all; table 3). In contrast, sex, alcohol consumption and BMI had significant interactions in the association of RA with NTM-PD (p value for interaction <0.05); the associations between RA and NTM-PD were more prominent in males, alcohol drinkers and obese participants than in their counterparts (p<0.05). Table 3Stratified analysis of NTM-PD risk according to RA statusSubgroupsRA statusNumber at risk (n)NTM (n)Duration (PY)IR per 1000 PYAdjusted HR*SexMaleNo77 55544337 687.70.13ReferenceYes15 5115565 647.80.844.93 (3.30–7.36)FemaleNo224 0201451 033 732.20.14ReferenceYes44 80492204 670.80.452.57 (1.97–3.34)P value for interaction0.007Age, years20–39No23 4104110 359.40.04Reference)Yes4682122 043.70.051.03 (0.12–9.24)40–64No197 80598917 372.20.11ReferenceYes39 56182182 496.70.453.36 (2.5–4.512)≥65No80 36087343 688.40.25ReferenceYes16 0726465 778.20.972.91 (2.1–4.03)P value for interaction0.496BMI, kg/m2Underweight (<18.5)No98743043 736.30.69Reference Yes26771511 689.41.281.61 (0.86–2.30)Normal (18.5–23.0)No118 207111539 900.30.21Reference Yes25 51187115 658.10.753.07 (2.31–4.08)Overweight (23.0–25.0)No74 45330342 481.30.09Reference Yes14 3012464 484.60.373.60 (2.1–6.16)Obese (≥25.0)No99 04118445 302.10.04Reference Yes17 8262178 486.50.275.67 (3.02–10.66)P value for interaction0.044SmokingNever smokerNo238 5551601 096 466.20.15ReferenceYes46 864107213 189.20.502.77 (2.16–3.55)Ex-smoker (<20 PY)No17 931976 407.10.12ReferenceYes3746715 883.10.443.01 (1.12–8.1)Ex-smoker (≥20 PY)No10 953646 165.70.13ReferenceYes27201111 042.51.005.59 (2.06–15.15)Current smoker (<20 PY)No19 355685 750.20.07ReferenceYes3626715 702.30.454.85 (1.63–4.45)Current smoker (≥20 PY)No14 781866 630.80.12ReferenceYes33591514 501.51.036.57 (2.78–15.52)P value for interaction0.220Alcohol intakeNoNo207 313155951 630.40.16ReferenceYes44 886110202 528.80.542.66 (2.08–3.41)YesNo82 97426370 174.90.07ReferenceYes13 7202960 492.50.485.57 (3.49–8.89)P value for interaction0.006Regular exerciseNoNo241 0461521 100 317.50.14ReferenceYes49 575125222 918.30.563.18 (2.50–4.05)YesNo60 52937271 102.40.14ReferenceYes10 7402247 400.20.462.78 (1.64–4.73)P value for interaction0.649Low incomeOtherNo232 3251541 058 286.40.15ReferenceYes46 554119210 664.90.563.02 (2.37–3.86)Q1, lowNo69 25035313 133.50.11ReferenceYes13 7612859 653.70.473.52 (2.14–5.8)P value for interaction0.589Diabetes mellitusNoNo263 9501721 209 228.90.14ReferenceYes52 718133239 102.50.563.11 (2.47–3.92)YesNo37 62517162 191.00.10ReferenceYes75971431 216.10.453.14 (1.54–6.38)P value for interactionNo263 9501721 209 228.90.140.981HypertensionNoNo193 444137886 160.80.15ReferenceYes36 54690166 2950.542.75 (2.1–3.6)YesNo108 13152485 259.10.11ReferenceYes23 76957104 023.70.554.00 (2.74–5.85)P value for interaction0.109DyslipidaemiaNo208 773134971 924.10.14NoYes41 046116189 226.10.61ReferenceNo92 80255399 495.80.143.47 (2.70–4.47)YesYes19 2693181 092.40.38ReferenceNo208 773134971 924.10.142.23 (1.44–3.49)P value for interaction0.092CKDNoNo282 2331761 281 501.70.14ReferenceYes55 391140248 619.20.563.22 (2.57–4.04)YesNo19 3421389 918.20.14ReferenceYes4924721 699.30.321.80 (0.72–4.52)P value for interaction0.229TuberculosisNoNo301 1641861 369 706.80.14ReferenceYes59 967139268 778.20.523.12 (2.49–3.90)YesNo41131713.11.75ReferenceYes34881540.45.192.90 (0.77–10.95)P value for interaction0.918Airway diseaseNoNo255 3691111166162.90.10ReferenceYes45 06464205 056.70.313.12 (2.29–4.25)YesNo46 20678205 257.10.38ReferenceYes15 2518365 261.91.273.10 (2.27–4.24)P value for interaction0.976*Adjusted for age, sex, BMI, smoking, alcohol consumption, physical activity, low income, diabetes mellitus, hypertension, dyslipidaemia, chronic kidney disease, airway diseases and tuberculosis.BMI, body mass index.NTM-PD, nontuberculous mycobacterial pulmonary disease; PY, pack-years; RA, rheumatoid arthritis. Stratified analysis of NTM-PD risk according to RA status Adjusted for age, sex, BMI, smoking, alcohol consumption, physical activity, low income, diabetes mellitus, hypertension, dyslipidaemia, chronic kidney disease, airway diseases and tuberculosis. BMI, body mass index.NTM-PD, nontuberculous mycobacterial pulmonary disease; PY, pack-years; RA, rheumatoid arthritis. Discussion This is the largest comprehensive study to evaluate the incidence of NTM-PD in participants with RA, as compared with the non-RA population, by using data from a nationwide cohort. Participants with RA had an NTM-PD incidence rate of 0.54 per 1000 person-years, which was approximately threefold higher than that in controls. Furthermore, additional subgroup analysis of the SPRA and SNRA groups based on serologic status showed that the risk of NTM-PD was higher only in participants with SPRA. Three longitudinal studies have compared the risk of NTM-PD in participants with RA and controls, and these studies consistently showed a higher incidence of NTM-PD in patients with RA compared with controls13 18 19; a population-based study in Canada demonstrated a 2.1-fold increased risk for NTM disease among patients with RA compared with controls.13 Two Taiwanese population-based studies reported that NTM-PD was 4.2- and 6.2-fold higher among patients with RA than among controls.18 19 Compared with Canadian and our study results, the risk of NTM-PD in patients with RA was especially higher in Taiwanese studies. Although the reasons are not clear, it might be related to unadjusted confounders, such as BMI and lifestyles (eg, alcohol consumption), that might be related to NTM-PD risk. In contrast, the risk of NTM-PD in patients with RA was lower in the Canadian study compared with Taiwanese and our study. Although there might be several reasons for this phenomenon, ethnicity could be a reason; a recent study showed that the risk of NTM-PD was higher in Asians than other ethnicities even considering BMI33 (online supplemental table 1). To the best of our knowledge, by classifying the serological status of RA, this is the first study to show that the risk of NTM-PD is significantly increased in SPRA. Supporting our findings, in an age-matched and sex-matched case-control study of RA patients with or without NTM-PD at a ratio of 1:5, the rheumotoid Factor (RF) and anti-CCP positivity rates were higher in RA patients with NTM-PD than in those without NTM-PD.15 Although the reasons for this are not yet well understood, the association may be explained by RA disease activity. It is well known that anti-CCP positivity is associated with RA development and deterioration.34 In addition, increased disease activity may have led to increased immunosuppressive drug use, which could increase the risk of NTM-PD. Overall, the increased risk of NTM-PD in SPRA may be the combined result of increased systemic inflammation and accompanying intense immunosuppressive drugs. Nevertheless, the possibility of a reverse association should also be considered. Chronic inflammation related to NTM-PD itself may contribute to RF positivity, particularly given that the diagnosis of NTM-PD is often delayed. Moreover, RF positivity is not specific to RA and can be observed in other chronic inflammatory conditions, which may further complicate the interpretation of this association. Interestingly, our stratified analysis showed that the association between RA and NTM-PD was especially prominent among obese participants and males as compared with their counterparts. Although the reason for this phenomenon cannot be fully explained, given the observational nature of our study and considering that the variables of underweight and female themselves are risk factors for NTM-PD, the extent to which RA contributes to the occurrence of NTM-PD in these patients can be interpreted as low. In contrast, the contribution of RA to the occurrence of NTM-PD in males or obese individuals is relatively high. In addition, it may be associated with increased disease activity in the obese population.35 However, owing to the absence of laboratory and radiological results, we could not consider this factor in our study. The higher association of NTM-PD in males than females may also be related to the higher prevalence of RA-related structural lung disease in males than in females.36 Although we adjusted for airway diseases and a history of TB, there might have been an underestimation in the evaluation of RA-related structural lung diseases because focal or non-severe diseases can only be detected on CT, which is not routinely performed. Our study has several limitations. First, our study may have a selection bias because we used health screening data, in which more healthy participants were likely to be included. Second, because our database did not contain laboratory and radiological test results, we could not incorporate these factors into our analysis. Future studies should include this data. Third, this study was conducted on the Korean population. Thus, studies in other countries and ethnicities are required to obtain generalisable findings. Fourth, data on immunosuppressive medications such as prednisone and anti-TNF agents were not available, potentially resulting in residual confounding. Fifth, species-level information on NTM was lacking, precluding analysis of species-specific risk profiles. Finally, information on the initiation and timing of NTM treatment in patients with coexisting conditions was not captured. Also, although the study had a longitudinal design, follow-up data on patient outcomes such as treatment response, mortality or disease course were not available. Future studies incorporating microbiological and clinical datasets with detailed outcome information across diverse populations are warranted. In summary, the incidence of NTM-PD in patients with RA was higher than that in patients without RA, which was significant only for SPRA. Supplementary material Footnotes Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea (RS-2025-00557268 and RS-2020-NR049557). This work was supported by the research fund of Hayang University (HY-202500000001668). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Data availability statement Data are available upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available upon reasonable request.